From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
Article in Diagnostics (December 2023)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases.
Article in Clinical Journal of the American Society of Nephrology (December 2023)
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
Article in Expert Opinion on Pharmacotherapy (June 2023)